$197.57 general Payment -- Merck & Co to Dr. Benjamin Cook

Merck & Co. payment to Infectious Disease specialist for services related to Skyrizi

This page provides a detailed analysis of a $197.57 general payment from Merck & Co to Dr. Benjamin Cook. Data is from the CMS Open Payments (Sunshine Act) database.

Payment Details

FieldValue
Amount$197.57
Payment Typegeneral
Payment NatureCompensation for services other than consulting
Pharmaceutical CompanyMerck & Co
PhysicianDr. Benjamin Cook
NPI Number1100370483
Physician SpecialtyInfectious Disease
LocationCincinnati, OH
Date of Payment2025-05-18
Related Drug/DeviceSkyrizi
Conflict AssessmentLow -- Routine

AI-Powered Analysis of This Payment

The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.

Merck & Co made a $197.57 general payment to Benjamin Cook, a Infectious Disease specialist in Cincinnati, OH. The payment was associated with Skyrizi. The payment of $197.57 to Dr. Benjamin Cook from Merck & Co. is for services other than consulting. The payment is associated with the drug Skyrizi, indicating a potential relationship with its promotion or use. This record represents a single, relatively small payment, suggesting it may not be indicative of a large-scale relationship.

Patient Guidance: What This Payment Means for You

This payment information is for transparency and does not necessarily reflect your personal treatment decisions or outcomes. Always discuss your treatment options with your healthcare provider and ask about alternatives.

Payment Context: Is This Amount Normal?

Payments for services other than consulting are common in the pharmaceutical industry, but the specific context for this $197.57 payment to an Infectious Disease specialist for Skyrizi is not detailed.

Regulatory Context: Sunshine Act Requirements

This payment is reported under the Physician Payments Sunshine Act, part of the Affordable Care Act, which requires manufacturers of drugs and medical devices to report payments made to physicians and teaching hospitals.

Related Topics

This payment is related to the following healthcare transparency topics:

Understanding general Payments

general payments are one of several categories of financial transfers from pharmaceutical and medical device companies to physicians that must be reported under the Sunshine Act. Understanding the type and context of a payment is important for evaluating its significance. Not all payments are equal -- a research grant has very different implications than a promotional speaking fee.

Frequently Asked Questions About This Payment

What was this $197.57 payment for?

This was a general payment of $197.57 from Merck & Co to Benjamin Cook, categorized as "Compensation for services other than consulting". It was associated with Skyrizi. The payment was reported under the Sunshine Act (CMS Open Payments).

Does Benjamin Cook accept pharmaceutical money?

Yes, Benjamin Cook received this $197.57 payment from Merck & Co. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Benjamin Cook's full payment history on the CMS Open Payments database or on this site.

Is it legal for doctors to accept pharma payments?

Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.

Should I be concerned about this general payment?

A general payment of $197.57 should be evaluated in context. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.

How do I talk to my doctor about pharma relationships?

You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.

What types of pharma payments are most concerning?

Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.

Does pharma money affect what my doctor prescribes?

Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.

How does this compare to other doctors in Infectious Disease?

To compare this payment against Infectious Disease averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Infectious Disease physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.

What does this payment reveal about Benjamin Cook's relationship with Merck & Co?

The payment date is in the future (May 18, 2025). This $197.57 general payment is part of the transparency data reported under the Sunshine Act.

Is this payment amount typical for Infectious Disease?

The payment amount is modest ($197.57).

What should patients do after learning about this payment?

This payment information is for transparency and does not necessarily reflect your personal treatment decisions or outcomes.

What else should I know about this general payment?

The payment is categorized as 'general' and for 'compensation for services other than consulting'.

Related Reports

Data from CMS Open Payments. Payment does not imply wrongdoing. Consult your healthcare provider about any concerns.